КОМПОЗИЦИЯ И СПОСОБЫ ДЛЯ РАЗДЕЛЕНИЯ КЛЕТОК

Изобретение относится к области медицины и касается композиции и способов для разделения клеток на основе агглютинации. Эти реагенты включают раствор декстрана, анти-гликофорин А-антитело, анти-СD15-антитело, анти-СD9-антитело и антитела, выбранные из группы, включающей анти-СD3-антитело, анти-СD72-антитело, анти-СD16-антитело, анти-СD4-антитело, анти-СD8-антитело и анти-СD2-антитело. Преимущество изобретения заключается в разработке композиции для выделения клеток крови даже редких клеточных типов с высоким выходом. 3 н. и 31 з.п. ф-лы, 17 табл.

ДЕТЕКТИРОВАНИЕ CD20 ПРИ ОТТОРЖЕНИИ ТРАНСПЛАНТАТА

... 1. Способ лечения отторжения трансплантата у пациента, включающий в себя (a) детектирование CD20 в образце, полученном из огранизма пациента; и (b) если в образце детектируется CD20, введение CD20-антагониста пациенту в количестве, эффективном для лечения отторжения трансплантата. 2. Способ по п.1, согласно которому образец является биопсийным образцом, полученным из организма пациента перед трансплантацией. 3. Способ по п.1, согласно которому образец является биопсийным образцом трансплантированного пересадочного материала. 4. Способ по п.1, согласно которому на стадии (b) лечат отторжение трансплантата сóлидного органа. 5. Способ по п.4, согласно которому сóлидный орган представляет собой легкое. 6. Способ по п.1, согласно которому антагонист содержит антитело. 7. Способ по п.6, согласно которому антитело не конъюгировано с цитотоксическим агентом. 8. Способ по п.6, согласно которому антитело содержит ритуксимаб. 9. Способ по п.6, согласно которому антитело содержит гуманизированное [ ...

КОМПОЗИЦИЯ И СПОСОБЫ ДЛЯ РАЗДЕЛЕНИЯ КЛЕТОК

... 1. Композиция, содержащая а) декстран; b) анти-гликофорин А-антитело; с) анти-CD15-антитело; d) анти-CD9-антитело и е) антитело, выбранное из группы, состоящей из анти-CD3-антитела, анти-CD72-антитела, анти-CD16-антитела, анти-CD4-антитела, анти-CD8-антитела и анти-CD2-антитела. 2. Композиция по п.1, дополнительно содержащая гепарин. 3. Композиция по п.1, дополнительно содержащая двухвалентные катионы. 4. Композиция по п.3, где указанные двухвалентные катионы являются Са+2. 5. Композиция по п.3, где указанные двухвалентные катионы являются Mg+2. 6. Композиция по п.1, дополнительно содержащая забуференный фосфатом солевой раствор. 7. Композиция по п.1, где рН указанной композиции находится между 6,8 и 7,8. 8. Композиция по п.1, где рН указанной композиции находится между 7,2 и 7,4. 9. Композиция по п.1, где указанное анти-гликофорин А-антитело является моноклональным. 10. Композиция по п.1, где указанное анти-гликофорин А-антитело является IgM-антителом. 11. Композиция по п.1, где указанное ...

TESTSATZ UND VERFAHREN ZUR BESTIMMUNG VON PESTIZIDEN

IMIDAZOLDERIVATE ALS HISTAMIN-H3-MODULATOREN

VERFAHREN ZUR IDENTIFIZIERUNG EINZELNER AKTIVER EINHEITEN AUS KOMPLEXEN GEMISCHEN

LEUKOZYTEN-ADHÄSIONS-INHIBITOR.

Identifizierung von Antigenen durch xenogene, allogene oder autologe Antikörper-vermittelte Präzipitation

Verfahren zum Auffinden von Antigenen mit den nachfolgenden Schritten: a) Herstellen eines interessierende Antigene enthaltenden Proteinlysats aus einem zu untersuchenden Zellmaterial eines Spenders; b) Inkubieren des Proteinlysats mit allogenem, xenogenem und/oder autologem Serum, Aszites und/oder Pleuralflüssigkeit, die jeweils Antikörper enthalten, die im Laufe einer humoralen Immunantwort oder einer Autoimmunantwort auf die Antigene gebildet wurden, um eine spezifische Bindung der Antikörper an die Antigene des Proteinlysats zu erhalten, wobei die Antikörper an ein Trägermaterial gebunden vorliegen; c) Abtrennen der Antigen-Antikörper-Komplexe; d) Nachweisen der mit den Antikörpern spezifisch gebundenen Antigene; e) Vergleichen der nachgewiesenen Antigene mit Kontrollproben aus gesundem Zellmaterial und/oder aus dem Serum alleine und/oder aus dem Lysat alleine.

Protein markers for human benign prostatic hyperplasia(BPH)

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES AND ASSOCIATED DISEASES WITH BETA TRP (MTR1/LTRPC5/TRPM5)

RADIO LIGAND AND CONNECTION ASSAY

ANTIBODY FOR MORE APOPTOSEMARKER AND OPERATING TECHNIQUES

PROCEDURE FOR THE IDENTIFICATION OF MODULATORS OF THE HUMAN OREXIN-2-REZEPTORS

FOR THE HUMAN VANILLOID RECEPTOR VR3 CODING DNS

REKOMBINANTES FEL D 1 ALL GENE

ANTAGONISTIC ANTIBODY AGAINST PRO842

ANTIBODY AGAINST VLA-1

PROOF OF CANCER

COMPOSITIONS AND PROCEDURES FOR THE MODULATION OF TRANSPORT BY THE BLOOD-BRAIN BARRIER

PROCEDURE FOR THE PROGNOSIS OF KIDNEY CELL CARCINOMA AND TREATMENT SELECTION WITH CARBOANHYDRASE IX

ATYPICAL PROTEIN KINASE C ISOFORMEN ON ILLNESSES OF THE NERVOUS SYSTEM AND CANCER

TREATMENT AND PREVENTING OF NEOPLASMATI AND INFECTIOUS ILLNESSES WITH HEAT SHOCK/STRESS PROTEINS

AGGLUTRIMETRI ANALYSIS METHODS IN THE BLOOD

MODULATOR OF THE HUMAN MAST CELL ACTIVATION

ZYTOKIN LIGAND FOR THE TREATMENT OF ASTHMA AND BREATH WAY OVER REACTIVITY

PROCEDURE, COMPOSITIONS AND CONNECTING TESTS FOR THE INHIBITION AMYLOID BETA PROTEINPRODUKTION

CHIMÄRE CHEMOKINREZEPTORPOLYPEPTIDE

COMPOSITIONS AND USES FOR THE STABILIZATION OF TRANSTHYRETIN AND FOR THE INHIBITION OF TRANSTHYRETIN FEHLFALTUNG

PROCEDURE AND COMPOSITIONS FOR THE IDENTIFICATION OF PROSTATAKREBS OR A HUMORALEN AN IMMUNE ANSWER APPROXIMATELY PROSTATAKREBS

TEST PROCEDURE FOR CANDIDATE CONNECTIONS ON SUSCEPTIBILITY FOR BILIÄRE ELIMINATION

HER-2-BINDUNGSANTAGONISTEN

IMMUNOCYTOKINE WITH MODULATED SELECTIVITY

CELLULAR RECEPTOR FOR ANTIPROLIFERATIVEN FACTOR

COMPOSITIONS AND PROCEDURES FOR IL13BIOMARKER

IMMUNOLOGICAL REGULATION PROCEDURE FOR THE REGULATION FROM ANTIBODIES IN BIOLOGICAL LIQUIDS AS WELL AS KITS TO THE EXECUTION OF THE PROCEDURE

NON--ENZYMATIC SYSTEM TO THE IMMUNOHISTOCHEMI FAERBEN AND REAGENTS.

NUCLEAR CONNECTION TEST FUER STEROIDREZEPTORSFUNKTION IN CANCER-WELL-BEHAVED CELLS.

IMMOBILIZED OLIGOPEPTIDE.

SYNTHETIC POLYPEPTIDE, THE BRAIN-SPECIFIC MRNAS TRANSLATIERTEN PROTEINOIDABSCHNITTEN CORRESPONDING, AS WELL AS YOUR APPLICATION FOR RECEPTORS, METHODS AND DIAGNOSTICS.

MONOCLONAL ANTIBODIES AGAINST RECEPTOR-INDUCED CONNECTION PLACES

IMPROVED IMMUNOHISTOCHEMI DYEING METHOD AND REAGENTS FOR IT

PARAOXONASE FROM SERUM

MOLECULES, ITSELF IN SELECTED ORGANS OR FABRICS THE INVIVO APPEARING AND PROCEEDING FOR YOUR IDENTIFICATION

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

PROCEDURE FOR THE IDENTIFICATION INTERNALIZING REDUCED BY TRANSMEMBRANREZEPTORAGONISTEN WITH

METHODS FOR ASSESSING ANTIANGIOGENIC AGENTS

PIBs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Immunoglobulin e vaccines and methods of use thereof

Sperm antigens associated with infertility

Intercellular adhesion molecule-3 and its binding ligands

Methods and compositions for the treatment and prevention of smooth muscle cell proliferation

Calcium receptor active molecules

Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Methods for isolating proteins expressed by dendritic cells

Chemokine receptors and disease

Revascularization of ischemic retinal tissue and screening method therefor

Microfluidic device and leucocyte antigen mediated microfluidic assay

Methods of screening for TRPM5 modulators

High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins

METHODS FOR DIAGNOSING HTLV-I-MEDIATED DISEASES

Pharmacological treatment of cognitive impairment

Methods and compositions for expressing negative-sense viral RNA in canine cells

The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.

METHOD OF IDENTIFYING GENES CONTROLLING DIFERENTIATION

Revascularization of ischemic retinal tissue and screening method therefor

The present invention provides a treatment method for promoting beneficial physiological revascularization of ischemic retinal tissue. The method comprises administering to a mammal suffering from a retinal vascular ischemia a therapeutically effective amount of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS), thereby simultaneously inhibiting pathological neovascularization while promoting beneficial physiological revascularization of damaged areas of the retina. In a preferred embodiment, the angiostatic fragment of TrpRS is T2-TrpRS or T2-TrpRS-GD. Preferably, the mammal is a human patient suffering from retinal ischemia. A screening method for identifying and evaluating therapeutic agents for treating retinal neovascular diseases is also disclosed.

A METHOD FOR SIMULTANEOUS DETECTION OF MULTIPLE MICROBIAL ANTIGENS IN BIOLOGICAL SPECIMENS FROM MASTITIC ANIMALS

METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES

METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING OF A MEMBRANE BOUND PRECURSOR PROTEIN

METHODS OF IDENTIFYING LONGEVITY MODULATORS AND THERAPEUTIC METHODS OF USE THEREOF

Methods for diagnosis, stratification, and monitoring of Alzheimer's disease

Diagnostic autoantibody profiles for the detection and diagnosis of neurodegenerative diseases

The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient- specific neurodegenerative disease diagnostic autoantibody profiles.

Device and method for detection of analytes

Method of screening candidate compounds for susceptibility to biliary excretion

A method of screening a candidate compound for susceptibility to biliary excretion by a hepatocyte transport protein. The method includes the steps of providing a culture of hepatocytes comprising a transport protein, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion by the transport protein. In some embodiments determining the amount of candidate compound in the bile canaliculus comprises inhibiting expression of the transport protein, measuring the amount of candidate compound in the bile canaliculus and comparing amounts of compound in the canalicules with and without inhibition of the transport protein. A difference in the amount of candidate compound in the canaliculus indicates susceptibility of the candidate ...

High Throughput Assay Systems And Methods For Identifying Agents That Alter Surface Expressions Of Intergral Membrane Proteins

Abstract Disclosed are high throughput assay systems and methods for identifying agents that alter the level of surface expression of integral membrane proteins, such as cardiac ion channels, in mammalian cells. Also disclosed are therapeutic methods of using agents identified using such methods.

Method for collecting and identifying markers of coronary disease

Regulation of human transient receptor potential channel

Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders

Screening for modulators of amyloid processing

Method of obtaining purified enterochromaffin cells and methods of using same

Immune complexes

Kcnmas as modifiers of the p53 pathway and methods of use

Pgc-1beta, a novel pgc-1 homologue and uses therefor

CYTOKINES AND CYTOKINE RECEPTORS WITH REDUCED IMMUNOGENICITY

PURIFICATION OF THE LEADING FRONT MIGRATORY CELLS

Assay for identifying inhibitors of fc gamma riii signaling

ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN

METHOD OF DETECTING AND PREVENTING ALZHEIMER'S DISEASE, PARTICULARLY AT PRODROMAL AND EARLY STAGES

METHODS FOR SELECTION FOR EFFICIENT ANIMAL GROWTH

Methods for identifying regulators of muscle mass using amylin receptors

Human anti-IL-23 antibodies, compositions, methods and uses

Abstract A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof and having applications in diagnostic and/or therapeutic compositions, methods 5 and devices.

Microfluidic devices and methods for use thereof in multicellular assays of secretion

Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible ...

PIF binding as a marker for immune dysregulation

Embodiments are directed to methods of examining preimplantation factor (PIF) binding to a subject's circulating immune cells as a marker for immune dysregulation. Some embodiments are directed to methods of detecting a level of immune dysregulation sufficient to cause recurrent pregnancy loss (RPL), methods of detecting a level of immune dysfunction sufficient to cause endometriosis, and methods of detecting a level of immune dysfunction comprising administering an effective amount of PIF or an analog thereof, and examining its binding to circulating immune cells. Within those methods, an about twenty percent change in PIF binding to a subject's circulating immune cells indicates a level of immune dysfunction.

Cellular permissivity factor for viruses, and uses thereof